Highest-materiality recent filing
GE HealthCare names William Grogan CFO effective Sept 14, 2026
William Grogan appointed CFO effective Sept 14, 2026, succeeding Jay Saccaro who stepped down for outside role.
New segment structure: AIS, Pharmaceutical Diagnostics (PDx), and Patient Care Solutions (PCS).
GE HealthCare Q2 revenue up 5.7% to $5.3B; EPS $1.24; reaffirms FY guidance
Revenue $5.3B (+5.7% YoY); organic revenue +3.5%; net income $561M vs $486M.
GE HealthCare CFO Saccaro resigns; preliminary Q2 revenue up 5.7%, EPS ahead of expectations
CFO Jay Saccaro resigns effective Aug 14, 2026; George Newcomb (Controller & CAO) named interim CFO.
GE HealthCare shareholders elect 8 directors, appoint lead director and committee chair
All eight director nominees elected at May 7 annual meeting; Kevin A. Lobo received lowest support with 332M votes for.
Revenue $5.1B (+7.4% reported, +2.9% organic); net income $389M vs $564M; diluted EPS $0.85 vs $1.23; adjusted EPS $0.99 vs $1.01.
GE HealthCare appoints Kevin Lobo (Stryker CEO) to Board; two directors not re-standing
Kevin A. Lobo, Chair & CEO of Stryker (NYSE: SYK), appointed to GEHC Board effective March 13, 2026.
GE HealthCare enters new $0.5B 364-day revolving credit facility, replacing prior facility
New $0.5B senior unsecured 364-day revolver matures February 25, 2027; replaces similarly sized 2025 facility terminated without penalty.
GE HealthCare Q4 revenue up 7.1% to $5.7B; 2026 EPS guidance $4.95-$5.15
Q4 revenue $5.7B (+7.1% YoY, organic +4.8%); diluted EPS $1.29, adjusted EPS $1.44.
GE HealthCare enters $750M term loan and issues $1.25B notes to fund Intelerad acquisition
Term loan credit facility of $750 million, three-year, unsecured, with JPMorgan as administrative agent.
GE HealthCare prices $1.25B notes: $600M at 4.150% due 2028, $650M at 4.950% due 2035
Priced $600M of 4.150% Notes due Dec 15, 2028 and $650M of 4.950% Notes due Dec 15, 2035.
Revenue $5.1B (+6% reported, +4% organic); organic orders +6% across all segments.
GE HealthCare Q2 beats, raises FY guidance; adj. EPS $1.06, organic rev +2%
Q2 revenue $5.0B, organic growth 2%; net income $486M vs $428M YoY.
Director Lloyd W. Howell, Jr. resigns from GE HealthCare board effective July 23, 2025
Lloyd W. Howell, Jr. resigned from the Board of Directors, effective immediately.
GE HealthCare issues $650M 4.800% notes due 2031 and $850M 5.500% notes due 2035
Issued $650M of 4.800% Senior Notes due 2031 and $850M of 5.500% Senior Notes due 2035.
GE HealthCare prices $1.5B notes offering: $650M 4.800% due 2031, $850M 5.500% due 2035
Priced $650M aggregate principal of 4.800% Notes due Jan 15, 2031 and $850M of 5.500% Notes due Jun 15, 2035.
GE HealthCare shareholders elect all 10 directors and approve say-on-pay at annual meeting
All 10 director nominees elected; Peter Arduini received ~357M votes for, 683K against.
GE HealthCare Q1 EPS $1.23, adj EPS $1.01; guides 2025 lower; authorizes $1B buyback
Revenue $4.8B (+3% reported, +4% organic); net income $564M vs $374M a year ago.
New $3.0B revolving credit facility matures March 27, 2030; new $0.5B 364-day facility matures March 26, 2026.
GE HealthCare reports Q4 EPS $1.57, adjusted EPS $1.45; guides FY2025 adjusted EPS $4.61-$4.75
Q4 revenue $5.3B, up 2% organic; net income $720M (13.5% margin) vs $403M (7.7%).
GE HealthCare enters $1B 364-day revolving credit facility, replacing prior facility
$1.0B senior unsecured revolving credit facility entered on Dec 11, 2024, maturing Dec 10, 2025.
GE HealthCare increases quarterly dividend 17% and sets medium-term targets at 2024 Investor Day
Quarterly cash dividend increased ~17%; no new per-share amount or dates stated in release.
GE HealthCare prices secondary offering of 13.3M shares; company gets no proceeds
Secondary offering of 13,281,302 shares priced; GE HealthCare receives no proceeds.
GE HealthCare Q3 adj EPS $1.14, revenue $4.9B; raises FY margin and EPS guidance
Revenue $4.9B, +1% YoY reported and organic; orders +1% organically, book-to-bill 1.04x.
GE HealthCare realigns IGT to AVS segment; recasts 2022-2024 segment revenue and EBIT
Effective July 1, 2024, Image Guided Therapies moved from Imaging to Ultrasound, renamed Advanced Visualization Solutions (AVS).
GE HealthCare prices upsized secondary offering of 15M shares at $86; no proceeds to company
Secondary offering upsized from 10M to 15M shares at $86.00/share; underwriters have option for 2.25M additional shares.
GE HealthCare issues $1B of 4.800% notes due 2029
Issued $1B aggregate principal amount of 4.800% Notes due August 14, 2029.
GE HealthCare prices $1B of 4.800% Notes due 2029
$1,000,000,000 aggregate principal of 4.800% Notes due August 14, 2029.
GE HealthCare reports Q2 2024: flat revenue, margin expansion, updates guidance
Revenue flat at $4.8B; organic revenue grew 1% YoY; net income margin improved to 8.9% from 8.7%.
GE HealthCare stockholders elect all 10 directors at 2024 annual meeting
All 10 director nominees elected with substantial majority; Peter Arduini received 358M votes for.
GE HealthCare reports Q1 2024 results: revenue flat organically, margins expand, reaffirms guidance
Revenues declined 1% to $4.6B; organic revenue approximately flat year-over-year.
GE HealthCare Imaging CEO Jan Makela resigns effective July 8, 2024
Jan Makela, Chief Executive Officer of Imaging, notified resignation on April 9, 2024.
Offering upsized to 14 million shares from previously announced 13 million.
GE HealthCare prices secondary offering of 13M shares at $82.25; GE to exchange debt for equity
Secondary offering of 13,000,000 GEHC shares priced at $82.25 per share ($80.605 net of underwriting discount).
GE HealthCare Q4 revenue $5.2B (+5% organic); FY24 guided adj EPS $4.20-$4.35
Q4 revenue $5.2B (+5% organic YoY); net income $403M, adj EPS $1.18; adj EBIT margin 16.1%.
GE HealthCare Q4 rev $5.2B (+5% organic), adj EPS $1.18; FY2024 adj EPS guide $4.20-$4.35
Q4 revenue $5.2B, up 5% organic YoY; net income $403M ($0.88 EPS) vs $554M ($1.21) prior year.
GE HealthCare Q4 revenue $5.2B (+5% organic); Adj EPS $1.18; guides FY2024 Adj EPS $4.20-4.35
Q4 revenue $5.2B (+5% organic); net income $403M vs $554M; Adj EBIT margin 16.1% vs 17.1%.
GE HealthCare Chief People Officer Betty Larson to resign effective March 21, 2024
Betty D. Larson notified the Company on Jan 31, 2024 of her resignation as Chief People Officer.
GE HealthCare enters $1.0B 364-day revolver, terminates prior facility
New $1.0B unsecured revolving credit facility matures Dec 11, 2024, with Citibank as agent.
GE HealthCare Q3 revenue +6% organic; raises low end of adjusted EPS guidance
Revenue $4.8B, up 5% reported and 6% organic YoY; net income $375M vs $487M.
GE HealthCare Q2 revenues up 9% organically; raises FY2023 guidance
Revenue $4.8B, +7% reported, +9% organic; organic orders +6%.
GE HealthCare shareholders elect 10 directors, approve say-on-pay at 2023 annual meeting
All 10 director nominees elected with >99% of votes cast (excluding broker non-votes) for each.
GE HealthCare names James Saccaro as CFO effective June 1, replacing Helmut Zodl
James Saccaro named CFO effective June 1, 2023, replacing Helmut Zodl.
GE HealthCare Q1 revenue up 12% organic; adjusted EPS $0.85; reaffirms FY guidance
Revenue $4.7B, +8% reported, +12% organic; strong across all segments: Imaging, Ultrasound, PCS, PDx.
CEO severance: 2.0x base + 2.0x bonus (non-CIC) or 2.99x each (CIC within 2 years); benefits for 24/36 months.
CEO Peter Arduini receives 39,425 RSUs, 109,994 stock options, and 70,683 PSUs under 2023 LTIP.
GE HealthCare forms JV with Sinopharm subsidiary CMDC for China medical equipment
JV with China National Medical Device Co. (CMDC), a Sinopharm unit, to develop, manufacture, and commercialize medical equipment.
Founders Grants of RSUs and stock options approved for ~8,200 leaders, including CEO and NEOs, post-spin-off.
GE HealthCare Q4 revenue $4.9B, adj EPS $1.31; FY23 adj EPS guidance $3.60-$3.75
Q4 revenue $4.9B (+8% reported, +13% organic); net income $554M, EPS $1.21, adjusted EPS $1.31.
GE HealthCare preliminary Q4 revenue ~$4.9B (+7% YoY); 2023 organic growth guidance 5-7%
Q4 2022 revenue ~$4.9B, up ~7% YoY; organic revenue growth ~12% YoY.
On August 13, 2026, the Board of Directors (the “Board”) of GE HealthCare Technologies Inc. (“GE HealthCare”) appointed William K. Grogan as Chief Financial Officer, effective September 14, 2026.
George A. Newcomb, who currently serves as GE HealthCare’s interim Chief Financial Officer, will cease serving in that interim role on September 14, 2026, and will continue serving as GE HealthCare’s Controller and Chief Accounting Officer.
On July 23, 2026, GE HealthCare named George Newcomb, Controller and Chief Accounting Officer, as interim Chief Financial Officer, effective August 14, 2026.
On July 21, 2026, James K. (Jay) Saccaro notified GE HealthCare that he will resign as Chief Financial Officer for a role outside of the medical technology industry.
On April 9, 2024, Jan Makela, Chief Executive Officer, Imaging, notified GE HealthCare Technologies Inc. (the “Company”) that he will be resigning from his role at the Company to become the chief executive officer of a private company that is not one of the Company’s competitors.
On January 31, 2024, Betty D. Larson, Chief People Officer, notified GE HealthCare Technologies Inc. (the “Company”) that she will be resigning from her role at the Company and that her last day at the Company will be March 21, 2024.
On May 4, 2023, GE HealthCare Technologies Inc. (“GE HealthCare” or “we”) named James K. (Jay) Saccaro our Vice President and Chief Financial Officer, effective June 1, 2023.
Mr. Saccaro will replace Helmut Zodl, who will cease to be our Chief Financial Officer and will become our Global Vice President, Special Projects and TSA Separation, effective June 1, 2023.
Tomislav Mihaljevic 58 Talent, Culture, and Compensation Committee and Nominating and Governance Committee
Phoebe L. Yang 53 Talent, Culture, and Compensation Committee and Nominating and Governance Committee
Peter J. Arduini 58 None
Lloyd W. Howell, Jr. 56 Audit Committee and Talent, Culture, and Compensation Committee
Max materiality 0.85 · Median 0.60 · Most common event earnings